

BCMA/TNFRSF17 Protein, Human, Recombinant, AF488-Labeled

General Information

Synonyms:	BCM;TNFRSF13A;BCMA;CD269
Protein Construction:	A DNA sequence encoding the extracellular domain (Met1-Ala54) of human TNFRSF17 (NP_001183.2) was expressed with a C-terminal polyhistidine tag. The protein is site-specifically conjugated with AF 488 (Excitation Max.= 495 nm, Emission Max.= 519 nm).
Species:	Human
Expression Host:	HEK293 Cells
Accession:	Q02223-1
Molecular Weight:	11.8 kDa (predicted)

QC Testing

Biological Activity:	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	≥ 90% as determined by SDS-PAGE.
Endotoxin:	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation:	This product is Lyophilized from sterile PBS, pH 7.4, with 5 %-8 % trehalose. Please contact us for any concerns or special requirements. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Preparation and Storage

Reconstitution:	Please refer to the lot-specific COA.
Stability & Storage:	Twelve months from date of receipt at -20°C to -70°C in lyophilized form and 3 months at -70°C under sterile conditions after reconstitution. Protect from prolonged exposure to light and avoid repeated freeze-thaw cycles. <small>Actual storage temperature shall be subject to the COA.</small>
Shipping:	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF- κ B and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor

A DRUG SCREENING EXPERT

for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481